A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury

Celine Lakra,Helen Cohen

DOI: https://doi.org/10.1080/10790268.2020.1848278

2020-12-02

Abstract:Botulinum Toxin type A (BTX-A) has historically been used as a treatment to reduce spasticity. However, its potential to treat neuropathic pain is increasingly being recognized in the literature. This clinical review examines the evidence regarding the use of BTX-A in directly treating neuropathic pain in the spinal cord injured population.An electronic literature search was conducted in MEDLINE, PubMed and Scopus from inception to May 2020. The key words 'spinal cord injury' AND 'neuropathic pain' AND 'botulinum toxin' AND 'human' were used. The literature search produced a total of 65 results of which 14 duplicates were removed. There was 1 additional paper included following a manual search, providing a total of 52 papers. Taking into account inclusion and exclusion criteria, 2 case reports and 2 randomized control trials were reviewed.While there are multiple studies published on the use of BTX-A to manage neuropathic pain in other patient populations, there is very little published on its potential to treat spinal cord injury-related neuropathic pain. The provisional data provides some evidence that subcutaneous injection of BTX-A may benefit this patient group, although dosing and application schedules remain untested, and information on longer-term complications has yet to be been collected.While early results are interesting, the quality and quantity of research published is not yet high enough to provide formal guidance on the use of BTX-A in treating central neuropathic pain in the spinal cord injury population. Further high-quality research is therefore recommended going forward.